万赛维怎么用？

(Valganciclovir hydrochloride) was developed by Roche and approved by the FDA in March 2001. It is a guanine analog antiviral drug and is commonly used for cytomegalovirus infections. It is the L-valyl ester of ganciclovir. It is a prodrug of ganciclovir and is rapidly converted into ganciclovir by gastrointestinal and hepatic esterases after oral administration.

How should patients use Valganciclovir Hydrochloride?

When Valganciclovir hydrochloride is used to prevent CMV infection in adult patients after organ transplantation, the recommended dose for kidney transplant patients is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 200 days after transplantation. For patients who have received a solid organ transplant other than a kidney, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.

Pregnant and lactating women: Due to the rapid and large-scale conversion of valganciclovir into ganciclovir, studies on its reproductive toxicity have not been repeated. In animal experiments, ganciclovir caused reduced fertility and teratogenic effects. It is recommended that women of childbearing potential use effective contraceptive measures during treatment. Male patients are advised to use barrier contraception during treatment with valganciclovir hydrochloride tablets and for at least 90 days after discontinuation of treatment.

There are no safety data on valganciclovir hydrochloride tablets during human pregnancy. Pregnant women should avoid the use of valganciclovir hydrochloride tablets unless the benefits to the mother far outweigh the potential harm to the fetus.

The developmental effects of valganciclovir or cyclovir on perinatal and postnatal infants have not been studied, but it must be considered that ganciclovir may be excreted in breast milk and cause serious adverse reactions in infants. Therefore, the decision should be made to discontinue medication or discontinue breastfeeding when considering the possible benefits of Valganciclovir Hydrochloride in nursing mothers.

Pediatric use: No safety and efficacy data are available in these patients. Valganciclovir hydrochloride is not recommended for use in children because the pharmacokinetics of valganciclovir hydrochloride in these patients have not been established.